vimarsana.com

Latest Breaking News On - Bartlett family professor - Page 1 : vimarsana.com

Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

Dr Manish on the 5-Year Survival Outcomes From the KEYNOTE-590 Study in Esophageal Cancer

Manish A. Shah, MD, discusses the 5-year outcomes from the phase 3 KEYNOTE-590 study of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

Zolbetuximab Improves Survival in Patients with Stomach Cancer

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.